Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486468 · ClinicalTrials.gov registry record · Phase 3
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
A Phase 3 study of Uveitis and Uveitis, Posterior, sponsored by Texas Retina Associates.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05486468 is a Phase 3 study of Uveitis and Uveitis, Posterior that is actively recruiting participants, run by Texas Retina Associates. The registered enrollment target is 30 participants, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05486468, a Phase 3 study of Uveitis and Uveitis, Posterior, is actively recruiting participants, sponsored by Texas Retina Associates.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
Conditions Studied
Interventions
- DRUG Yutiq 0.18 MG Drug Implant
- OTHER Sham Injection
Study Locations (1)
Texas
- Texas Retina Associates - Plano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05486468
The ClinicalTrials.gov registry entry for NCT05486468 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower). The listed sponsor is Texas Retina Associates, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Yutiq 0.18 MG Drug Implant is the first listed.
NCT05486468 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05486468 about?
NCT05486468 is a clinical study titled "The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment". The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
What is the current status of trial NCT05486468?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2022-10-05. Estimated completion is 2026-12.
What conditions does trial NCT05486468 study?
This clinical trial studies the following conditions: Uveitis, Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Anterior.
What interventions are being tested in trial NCT05486468?
The interventions under investigation include: Yutiq 0.18 MG Drug Implant (DRUG), Sham Injection (OTHER).
Who is sponsoring clinical trial NCT05486468?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486468 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
ACTIVE NOT RECRUITING · Phase 3
-
Study of Difluprednate in the Treatment of Uveitis
COMPLETED · Phase 3
-
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
COMPLETED · Phase 3
-
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
COMPLETED · Phase 3
-
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
COMPLETED · Phase 3
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.